| 79. |
Norton R, Caserta MT, Breese Hall C et al. Detection of human herpesvirus 6 by reverse trancsription-PCR. J Clin Microbiol 1999;37:3672-3675. |
| 80. |
Balfour H. Antiviral drugs. N Engl J Med 1999;340:1255-1268. |
| 81. |
Russler SK, Tapper MA, and Carrigan DR. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir. Lancet 1989; 2:382. |
| 82. |
Burns WH and Sanford GR. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 1990; 162:634-637. |
| 83. |
Reyman D, Naesens L, Balzarini J et al. Antiviral activity of selected nucleoside analogues against human herpesvirus-6. Antiviral Res 1995;28:343-357. |
| 84. |
Mookerjee BP and Vogelsang G. Human herpes virus 6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transpl 1997; 20:905-906. |
| 85. |
Cole PD, Stiles J, Boulad F et al. Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis 1998;27:653-654. |
| 86. |
Lerner MA, Zervos M, Dworkin HJ et al. New cardiomyopathy: Pilot study of intravenous ganciclovir in a subset of the chronic fatigue syndrome. Infect Dis Clin Pract 1997;6:110-117. |
| 87. |
Rudick RA, Cohen JA, Weinstock-Guttman B et al. Management of multiple sclerosis. N Engl J Med 1997;337:1604-1611. |
| 88. |
Sorenson PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281. |
| 89. |
Lloyd A, Kickie I, Wakefield D et al. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-568. |
| 90. |
Dwyer JM. The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: Kirkpatrick CH, Burger DR and Lawrence HS eds. Immunobiology of transfer factor. New York Academic Press 1983:233-243. |
| 91. |
Jones JF, Jeter WS, Fulginiti VA et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-124. |
| 92. |
Steele RW, Myers MG and Monroe VM. Transfer factor for the prevention of varicella-zoster infection in childhood. N Engl J Med 1980;303:355-359. |
| 93. |
Viza D, Vich JM, Phillips J et al. Orally administered specific transfer factor for the treatment of herpesvirus infections. Lymphok Res 1985;4:27-30. |
| 94. |
Fudenberg H and Pizza G. Transfer factor 1993: New frontiers. Progress in Drug Res 1994;42:309-400. |
| 95. |
Lang I, Nekam H, Gergely P et al. Effect of in vivo and in vitro treatment with dialyzable leukocyte extracts on human natural killer cell activity. Clin Immunol and Immunopathol 1982;25:139-144. |
| 96. |
Wilson GB and Paddock GV. Process of obtaining transfer factor from colostrum; transfer factor so obtained and use thereof. U.S. Patent 4,816,563 (1989). |
| 97. |
Berg D, Berg LH, and Couvaras J. Does adding anticoagulant therapy improve CFS patients symptoms, since there appears to be a correlation between a hypercoaguable state from immune activation? J Chronic Fatigue Syndr 1999;3/4:114-115. |
| 98. |
Immergluck LC, Domowicz MS, Schwartz NB et al. Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells. J Gen Virol 1998;79:549-559. |
| 99. |
Compton T, Nowlin DM and Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 1993;193:834-841. |
